Cargando…

ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS

BACKGROUND: Gastric and esophagogastric junction adenocarcinoma are responsible for approximately 13.5% of cancer-related deaths. Given the fact that these tumors are not typically detected until they are already in the advanced stages, neoadjuvancy plays a fundamental role in improving long-term su...

Descripción completa

Detalles Bibliográficos
Autores principales: de CASTRO, Juliana Silveira Lima, PELOSOF, Adriane Graicer, de ANDRADE-CABRAL, João Guilherme Guerra, SERAPHIM, Alvaro Moura, TAGLIERI, Eloy, COIMBRA, Felipe Jose Fernandez, ZITRON, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Colégio Brasileiro de Cirurgia Digestiva 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8735268/
https://www.ncbi.nlm.nih.gov/pubmed/35019128
http://dx.doi.org/10.1590/0102-672020210002e1616
_version_ 1784628193961967616
author de CASTRO, Juliana Silveira Lima
PELOSOF, Adriane Graicer
de ANDRADE-CABRAL, João Guilherme Guerra
SERAPHIM, Alvaro Moura
TAGLIERI, Eloy
COIMBRA, Felipe Jose Fernandez
ZITRON, Claudia
author_facet de CASTRO, Juliana Silveira Lima
PELOSOF, Adriane Graicer
de ANDRADE-CABRAL, João Guilherme Guerra
SERAPHIM, Alvaro Moura
TAGLIERI, Eloy
COIMBRA, Felipe Jose Fernandez
ZITRON, Claudia
author_sort de CASTRO, Juliana Silveira Lima
collection PubMed
description BACKGROUND: Gastric and esophagogastric junction adenocarcinoma are responsible for approximately 13.5% of cancer-related deaths. Given the fact that these tumors are not typically detected until they are already in the advanced stages, neoadjuvancy plays a fundamental role in improving long-term survival. Identification of those with complete pathological response (pCR) after neoadjuvant chemotherapy (NAC) is a major challenge, with effects on organ preservation, extent of resection, and additional surgery. There is little or no information in the literature about which endoscopic signs should be evaluated after NAC, or even when such re-evaluation should occur. AIM: To describe the endoscopic aspects of patients with gastric and esophagogastric junction adenocarcinomas who underwent NAC and achieved pCR, and to determine the accuracy of esophagogastroduodenoscopy (EGD) in predicting the pCR. METHODS: A survey was conducted of the medical records of patients with these tumors who were submitted to gastrectomy after NAC, with anatomopathological result of pCR. RESULTS: Twenty-nine patients were identified who achieved pCR after NAC within the study period. Endoscopic responses were used to classify patients into two groups: G1-endoscopic findings consistent with pCR and G2-endoscopic findings not consistent with pCR. Endoscopic evaluation in G1 was present in an equal percentage (47.4%; p=0.28) in Borrmann classification II and III. In this group, the predominance was in the gastric body (57.9%; p=0.14), intestinal subtype with 42.1% (p=0.75), undifferentiated degree, 62.5% (p=0.78), Herb+ in 73.3% (p=0.68). The most significant finding, however, was that the time interval between NAC and EGD was longer for G1 than G2 (24.4 vs. 10.2 days, p=0.008). CONCLUSION: EGD after NAC seems to be a useful tool for predicting pCR, and it may be possible to use it to create a reliable response classification. In addition, the time interval between NAC and EGD appears to significantly influence the predictive power of endoscopy for pCR.
format Online
Article
Text
id pubmed-8735268
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Colégio Brasileiro de Cirurgia Digestiva
record_format MEDLINE/PubMed
spelling pubmed-87352682022-01-21 ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS de CASTRO, Juliana Silveira Lima PELOSOF, Adriane Graicer de ANDRADE-CABRAL, João Guilherme Guerra SERAPHIM, Alvaro Moura TAGLIERI, Eloy COIMBRA, Felipe Jose Fernandez ZITRON, Claudia Arq Bras Cir Dig Original Article BACKGROUND: Gastric and esophagogastric junction adenocarcinoma are responsible for approximately 13.5% of cancer-related deaths. Given the fact that these tumors are not typically detected until they are already in the advanced stages, neoadjuvancy plays a fundamental role in improving long-term survival. Identification of those with complete pathological response (pCR) after neoadjuvant chemotherapy (NAC) is a major challenge, with effects on organ preservation, extent of resection, and additional surgery. There is little or no information in the literature about which endoscopic signs should be evaluated after NAC, or even when such re-evaluation should occur. AIM: To describe the endoscopic aspects of patients with gastric and esophagogastric junction adenocarcinomas who underwent NAC and achieved pCR, and to determine the accuracy of esophagogastroduodenoscopy (EGD) in predicting the pCR. METHODS: A survey was conducted of the medical records of patients with these tumors who were submitted to gastrectomy after NAC, with anatomopathological result of pCR. RESULTS: Twenty-nine patients were identified who achieved pCR after NAC within the study period. Endoscopic responses were used to classify patients into two groups: G1-endoscopic findings consistent with pCR and G2-endoscopic findings not consistent with pCR. Endoscopic evaluation in G1 was present in an equal percentage (47.4%; p=0.28) in Borrmann classification II and III. In this group, the predominance was in the gastric body (57.9%; p=0.14), intestinal subtype with 42.1% (p=0.75), undifferentiated degree, 62.5% (p=0.78), Herb+ in 73.3% (p=0.68). The most significant finding, however, was that the time interval between NAC and EGD was longer for G1 than G2 (24.4 vs. 10.2 days, p=0.008). CONCLUSION: EGD after NAC seems to be a useful tool for predicting pCR, and it may be possible to use it to create a reliable response classification. In addition, the time interval between NAC and EGD appears to significantly influence the predictive power of endoscopy for pCR. Colégio Brasileiro de Cirurgia Digestiva 2021-12-17 /pmc/articles/PMC8735268/ /pubmed/35019128 http://dx.doi.org/10.1590/0102-672020210002e1616 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Original Article
de CASTRO, Juliana Silveira Lima
PELOSOF, Adriane Graicer
de ANDRADE-CABRAL, João Guilherme Guerra
SERAPHIM, Alvaro Moura
TAGLIERI, Eloy
COIMBRA, Felipe Jose Fernandez
ZITRON, Claudia
ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS
title ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS
title_full ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS
title_fullStr ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS
title_full_unstemmed ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS
title_short ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS
title_sort endoscopic characteristics of patients with complete pathological response after neoadjuvant chemotherapy for gastric and esophagogastric junction adenocarcinomas
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8735268/
https://www.ncbi.nlm.nih.gov/pubmed/35019128
http://dx.doi.org/10.1590/0102-672020210002e1616
work_keys_str_mv AT decastrojulianasilveiralima endoscopiccharacteristicsofpatientswithcompletepathologicalresponseafterneoadjuvantchemotherapyforgastricandesophagogastricjunctionadenocarcinomas
AT pelosofadrianegraicer endoscopiccharacteristicsofpatientswithcompletepathologicalresponseafterneoadjuvantchemotherapyforgastricandesophagogastricjunctionadenocarcinomas
AT deandradecabraljoaoguilhermeguerra endoscopiccharacteristicsofpatientswithcompletepathologicalresponseafterneoadjuvantchemotherapyforgastricandesophagogastricjunctionadenocarcinomas
AT seraphimalvaromoura endoscopiccharacteristicsofpatientswithcompletepathologicalresponseafterneoadjuvantchemotherapyforgastricandesophagogastricjunctionadenocarcinomas
AT taglierieloy endoscopiccharacteristicsofpatientswithcompletepathologicalresponseafterneoadjuvantchemotherapyforgastricandesophagogastricjunctionadenocarcinomas
AT coimbrafelipejosefernandez endoscopiccharacteristicsofpatientswithcompletepathologicalresponseafterneoadjuvantchemotherapyforgastricandesophagogastricjunctionadenocarcinomas
AT zitronclaudia endoscopiccharacteristicsofpatientswithcompletepathologicalresponseafterneoadjuvantchemotherapyforgastricandesophagogastricjunctionadenocarcinomas